CA-170
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C12H20N6O7 |
Molar mass | 360.327 g·mol−1 |
3D model (JSmol) | |
| |
|
CA-170 is an investigational new drug being evaluated as an immune checkpoint inhibitor for the treatment of cancer. Developed by Aurigene Oncology, it is an orally available small molecule designed to selectively inhibit the immune checkpoint proteins PD-L1[1] and VISTA,[2] both of which are key negative regulators of T-cell activation implicated in cancer immune evasion.[3][4]
By targeting these immune pathways, CA-170 aims to restore and enhance the immune system’s ability to recognize and eliminate tumor cells, offering the potential for improved anti-tumor responses across a variety of cancers.[4][5]
References
[edit]- ^ Sasikumar PG, Ramachandra M (2022). "Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development". Frontiers in Immunology. 13: 752065. doi:10.3389/fimmu.2022.752065. PMC 9108255. PMID 35585982.
- ^ Wu C, Cao X, Zhang X (October 2021). "VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses". RSC Medicinal Chemistry. 12 (10): 1672–1679. doi:10.1039/d1md00185j. PMC 8528208. PMID 34778768.
- ^ "CA‑170". Curis, Inc. Retrieved 2025-06-22.
- ^ a b Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, et al. (June 2021). "PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy". Communications Biology. 4 (1): 699. doi:10.1038/s42003-021-02191-1. PMC 8187357. PMID 34103659.
- ^ Lee JJ, Powderly JD, Patel MR, Brody J, Hamilton EP, Infante JR, et al. (2017). "Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas". Journal of Clinical Oncology. 35 (15 suppl): TPS3099. doi:10.1200/JCO.2017.35.15_suppl.TPS3099.